The average of price targets set by Wall Street analysts indicates a potential upside of 171.1% in Urogen Pharma (URGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Urogen Pharma (URGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The average of price targets set by Wall Street analysts indicates a potential upside of 149% in Urogen Pharma (URGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.